~~<i id='86144A7137'><strike id='86144A7137'><tt id='86144A7137'><pre id='86144A7137'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

entertainment

author：Wikipedia 2025-10-01 23:03:07 - browse：53

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Hospitals warn Medicare's drug payment fix is ‘unlawful’

hotspot

focus

leisure time

focus

hotspot

AdobeHospitalsaretellinggovernmentofficialsitwouldbeillegaltoclawback$7.8billionaspartofaremedythati

WSS

What Mike Pence has said that could be used in a Donald Trump trial

Traditional Chinese medicine benefits explored in new JAMA study

ProMED, early warning system on disease outbreaks, in peril

A cyberattack has disrupted hospitals and health care in several states

2 US Navy sailors arrested for allegedly spying for China

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Wikipedia

entertainment

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Traditional Chinese medicine benefits explored in new JAMA study

Alkermes shareholders re

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

BioMarin wins approval for gene therapy to treat hemophilia A

WHO may add ‘noma' to its list of neglected tropical diseases

The cancer drug shortage isn’t new — and neither are the solutions

Biden calls for immediate release of Niger's president amid apparent coup

Guidelines to prevent youth baseball injuries need more muscle

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

focus

Meta's Zuckerberg and Chan on track to put $50 billion into science

Paying for Covid pills will soon shift to insurers

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Microsoft strikes partnership with Duke Health to advance health AI

My superpower is killing ticks

2 US Navy sailors arrested for allegedly spying for China

leisure time

focus

focus

hotspot